When was Vico founded?

Vico was founded in 2019 and raised its 1st funding round 1 year after it was founded.

Where is Vico located?

Vico is headquartered in Leiden, Netherlands.

How many employees does Vico have?

As of Jul 31, 2026, the latest employee count at Vico is 50.

Is Vico a funded company?

Vico is a funded company, having raised a total of $103M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jul 29, 2020.

When was the latest funding round of Vico?

Vico's latest funding was a $***** Series B round on Jun 24, 2024, with participation from 8 investors.

Where does Vico rank among its competitors?

Vico ranks 120th amongst 2969 active competitors, of which 996 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Vico?

Vico's top competitors include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Vico - 2026 Company Profile, Team, Funding & Competitors

Vico is a series B company based in Leiden (Netherlands), founded in 2019 by Gail Mandel and Luc Dochez. It operates as a Developer of RNA modulating therapies for genetic neurological diseases. Vico has raised $103M in funding from investors like Kurma Partners, Life Sciences Partners and Ackermans & van Haaren. The company has 2969 active competitors, including 996 funded and 724 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Biogen and PTC Therapeutics.

Company Details

Developer of RNA modulating therapies for genetic neurological diseases. The company uses VICOMER antisense oligonucleotide platform to design RNA modulating therapeutics to address specific genetic defects such as Rett syndrome, Alzheimer’s disease, Huntington disease, and more. The company's lead candidate is VO659 for multiple polyglutamine disorders, spinocerebellar ataxia type 3 and type 1 and Huntington’s disease.

Website: vicotx.com
Social
Email ID: *****@vicotx.com
Phone Number: +31 **********

Key Metrics

Founded Year

2019

Location

Leiden, Netherlands

Stage

Series B

Total Funding

$103M in 3 rounds

Latest Funding Round

Series B, Jun 24, 2024, $*****

Investors

Kurma Partners & 10 more

Ranked

120^th among 2969 active competitors

Employee Count

50 as on Jul 31, 2026

Similar Companies

Jazz Pharmaceuticals & 674 more

View Vico's full profile

Vico has raised a total funding of $103M over 3 rounds. Its first funding round was on Jul 29, 2020. Its latest funding round was a Series B round on Jun 24, 2024 for $*****. 8 investors participated in its latest round. Vico has 11 institutional investors.

Here is the list of recent funding rounds of Vico:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 24, 2024	2793474	Series B	1548979	1883068	1220035	7576932
Jan 05, 2024	3632438	Series B	3874116	7363882	1118953	Polaris Partners & 2 more
Jul 29, 2020	6213903	Series A	3904235	4382380	Life Sciences Partners & 1 more	Pontifax & 4 more

Access funding benchmarks and valuations. Sign up today!

View details of Vico's funding rounds and investors

The founders of Vico are Gail Mandel and Luc Dochez.

Here are the details of Vico's key team members:

Gail Mandel: Co-Founder of Vico. They are also an angel investor in 1 startup.
Luc Dochez: Co-Founder & CEO of Vico.
Contact Info: 1 email address

View details of Vico's Founder profiles and Board Members

Vico's employee count trend

Vico has 50 employees as of Jul 26. Here is Vico's employee count trend over the years:

Uncover Vico's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Vico include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Here is the list of Top 10 competitors of Vico, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
4th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
5th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
120th	Vico 2019, Leiden (Netherlands), Series B	Developer of RNA modulating therapies for genetic neurological diseases	$103M	Life Sciences Partners, EQT & 9 others	61/100